Spots Global Cancer Trial Database for pfs
Every month we try and update this database with for pfs cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome | NCT01053806 | Myelodysplastic... | 5-Azacytidine a... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT03376958 | Relapsed and Re... Diffuse Large B... | Apatinib | 14 Years - 70 Years | Zhengzhou University | |
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma | NCT03513601 | Diffuse Large B... | (R)-CHOP regime... (R)-CVP regimen | 70 Years - 85 Years | Zhengzhou University | |
| A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients | NCT03706690 | Carcinoma, Non-... | Durvalumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| A Real-world Study: Efficacy and Safety of Anlotinib for Advanced Non-small Cell Lung Cancer(NSCLC) | NCT04871997 | NSCLC | 18 Years - | Tongji Hospital | ||
| Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT01471444 | Disorder Relate... Leukemia Transplantation... | Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate | 3 Years - 70 Years | M.D. Anderson Cancer Center | |
| Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | NCT03422029 | Neuroendocrine ... | 177Lu-Dotatate ... | 18 Years - | Peking University | |
| Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma | NCT03168607 | Neuroendocrine ... | FOLFIRI Protoco... | 18 Years - | Peking University | |
| Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer | NCT02629718 | PFS OS Quality of Life | NACT (Paclitaxe... radical surgery | 18 Years - 65 Years | Sun Yat-sen University | |
| Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer | NCT01895257 | Colorectal Canc... | HAI-90Y radioem... systemic chemot... | 18 Years - 99 Years | Universiteit Antwerpen | |
| Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | NCT04083066 | Primary Central... | rituximab in co... | 14 Years - 75 Years | Zhengzhou University | |
| Combination of Metformin With Gefitinib to Treat NSCLC | NCT01864681 | NSCLC EGFR Gene Ampli... Advanced Cancer Stage IIIB NSCL... Stage IV NSCLC | Gefitinib and M... Gefitinib and p... | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer | NCT02072317 | Advanced Gastri... | taxel plus ralt... taxol | 18 Years - 75 Years | Fudan University | |
| Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor | NCT03279601 | Neuroendocrine ... | Capecitabine, D... Capecitabine, T... | 18 Years - | Peking University | |
| Combination of Metformin With Gefitinib to Treat NSCLC | NCT01864681 | NSCLC EGFR Gene Ampli... Advanced Cancer Stage IIIB NSCL... Stage IV NSCLC | Gefitinib and M... Gefitinib and p... | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC | NCT02037997 | Non Small Cell ... | docetaxel pemetrexed Erlotinib | 18 Years - | Fudan University | |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | NCT03376958 | Relapsed and Re... Diffuse Large B... | Apatinib | 14 Years - 70 Years | Zhengzhou University | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer | NCT04431791 | Colorectal Canc... | Regorafenib Fruquintinib | - | Peking University | |
| Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation | NCT03833154 | Carcinoma, Non-... | Durvalumab Placebo Osimertinib (si... | 18 Years - 130 Years | AstraZeneca | |
| A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients | NCT03706690 | Carcinoma, Non-... | Durvalumab Placebo | 18 Years - 130 Years | AstraZeneca | |
| Treatment of Primary CNS Lymphoma ( FTD ) | NCT05274139 | Primary CNS Lym... | HD-MTX-Ara-C re... FTD regimen | 14 Years - 69 Years | Zhengzhou University | |
| Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma | NCT05638984 | PFS | Decitabine Inje... tirelizumab | 18 Years - | Fudan University | |
| Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer | NCT05267288 | PFS | afatinib | 18 Years - 85 Years | Qingdao Central Hospital | |
| Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma | NCT03168594 | Neuroendocrine ... | irinotecan cisp... Etoposide cispl... | 18 Years - | Peking University | |
| Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome | NCT01053806 | Myelodysplastic... | 5-Azacytidine a... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | NCT04648319 | Cholangiocarcin... | BMS-936558 | 18 Years - | American University of Beirut Medical Center | |
| Treatment of Primary CNS Lymphoma ( FTD ) | NCT05274139 | Primary CNS Lym... | HD-MTX-Ara-C re... FTD regimen | 14 Years - 69 Years | Zhengzhou University | |
| Study for Patients With Lung Metastatic Advanced Gastric Cancer and NSCLC Treated With Apatinib | NCT03629691 | Gastric Cancer ... Lung Cancer | lung cavitation | 18 Years - 90 Years | The Affiliated Hospital of Qingdao University | |
| SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer | NCT01811277 | Biliary Tract C... Periampullary A... Pancreatic Canc... | SOX sequential ... | 18 Years - 75 Years | Peking University | |
| Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | NCT05988697 | NSCLC BRAF V600E Muta... Advanced Cancer Stage IIIB NSCL... Stage IV NSCLC | Combind asprin ... | 18 Years - 75 Years | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer | NCT02072317 | Advanced Gastri... | taxel plus ralt... taxol | 18 Years - 75 Years | Fudan University | |
| ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC | NCT01810367 | Non Small Cell ... | ABX Combined Wi... Gemcitabine Com... | 18 Years - 75 Years | Fudan University | |
| Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | NCT03422029 | Neuroendocrine ... | 177Lu-Dotatate ... | 18 Years - | Peking University | |
| Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL | NCT03707847 | ALK-Positive An... | Crizotinib Etoposide Capsu... Auto-HSCT | 14 Years - 65 Years | Zhengzhou University | |
| Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients | NCT01129336 | First or Second... Metastatic Dise... | Zoledronic acid Standard Therap... | 18 Years - | Novartis | |
| Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma | NCT03513601 | Diffuse Large B... | (R)-CHOP regime... (R)-CVP regimen | 70 Years - 85 Years | Zhengzhou University | |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | NCT04831658 | Primary Central... | the dose-escala... | 18 Years - 69 Years | Zhengzhou University | |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | NCT04831658 | Primary Central... | the dose-escala... | 18 Years - 69 Years | Zhengzhou University | |
| Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | NCT03631862 | Newly Diagnosed... | Apatinib CHOP Regimen | 14 Years - 70 Years | Zhengzhou University | |
| The Efficacy of Lymph Node Dissection for Stage IIICr of Cervical Cancer(CQGOG0103) | NCT04555226 | Cervical Cancer | Lymph node diss... Standard chemor... Chemoradiation | 18 Years - 70 Years | Chongqing University Cancer Hospital | |
| Treatment of Primary CNS Lymphoma ( FTD ) | NCT05274139 | Primary CNS Lym... | HD-MTX-Ara-C re... FTD regimen | 14 Years - 69 Years | Zhengzhou University | |
| Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma | NCT03513601 | Diffuse Large B... | (R)-CHOP regime... (R)-CVP regimen | 70 Years - 85 Years | Zhengzhou University | |
| Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor | NCT03279601 | Neuroendocrine ... | Capecitabine, D... Capecitabine, T... | 18 Years - | Peking University | |
| A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma | NCT03579082 | Diffuse Large B... | Decitabine | 14 Years - 65 Years | Zhengzhou University | |
| Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients | NCT01129336 | First or Second... Metastatic Dise... | Zoledronic acid Standard Therap... | 18 Years - | Novartis | |
| Allo HSCT Using RIC and PTCy for Hematological Diseases | NCT05805605 | Acute Myelogeno... Acute Lymphocyt... Biphenotypic Ac... Undifferentiate... Prolymphocytic ... Chronic Myeloge... Plasma Cell Leu... Myelodysplastic... Leukemia, Myelo... Myelodysplastic... Burkitt Lymphom... Relapsed T-Cell... Relapsed Chroni... Small Lymphocyt... Marginal Zone L... Follicular Lymp... Myeloproliferat... Myelofibrosis | Peripheral Bloo... Allopurinol 300... Fludarabine Cyclophosphamid... Bone Marrow Cel... Total Body Irra... Sirolimus Pill Mycophenolate M... | - 75 Years | Masonic Cancer Center, University of Minnesota | |
| Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT05773079 | Locally Advance... | Toripalimab | 18 Years - 70 Years | Nanfang Hospital, Southern Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
